1
|
Abstract
BACKGROUND Since its discovery, NLRP3 is almost never separated from its major role in the protein complex it forms with ASC, NEK7 and Caspase-1, the inflammasome. This key component of the innate immune response mediates the secretion of proinflammatory cytokines IL-1β and IL-18 involved in immune response to microbial infection and cellular damage. However, NLRP3 has also other functions that do not involve the inflammasome assembly nor the innate immune response. These non-canonical functions have been poorly studied. Nevertheless, NLRP3 is associated with different kind of diseases probably through its inflammasome dependent function as through its inflammasome independent functions. AIM OF THE REVIEW The study and understanding of the canonical and non-canonical functions of NLRP3 can help to better understand its involvement in various pathologies. In parallel, the description of the mechanisms of action and regulation of its various functions, can allow the identification of new therapeutic strategies. KEY SCIENTIFIC CONCEPTS OF THE REVIEW NLRP3 functions have mainly been studied in the context of the inflammasome, in myeloid cells and in totally deficient transgenic mice. However, for several year, the work of different teams has proven that NLRP3 is also expressed in other cell types where it has functions that are independent of the inflammasome. If these studies suggest that NLRP3 could play different roles in the cytoplasm or the nucleus of the cells, the mechanisms underlying NLRP3 non-canonical functions remain unclear. This is why we propose in this review an inventory of the canonical and non-canonical functions of NLRP3 and their impact in different pathologies.
Collapse
Affiliation(s)
- Théo Accogli
- Faculté des Sciences de Santé- University of Burgundy, Dijon 21000, FRANCE; CAdIR Team - Centre de Recherche INSERM - UMR 1231, Dijon 21000, FRANCE
| | - Christophe Hibos
- Faculté des Sciences de Santé- University of Burgundy, Dijon 21000, FRANCE; CAdIR Team - Centre de Recherche INSERM - UMR 1231, Dijon 21000, FRANCE; Université de Bourgogne Franche-Comté, Dijon 21000, FRANCE
| | - Frédérique Vegran
- Faculté des Sciences de Santé- University of Burgundy, Dijon 21000, FRANCE; CAdIR Team - Centre de Recherche INSERM - UMR 1231, Dijon 21000, FRANCE; Department of Biology and Pathology of Tumors - Centre anticancéreux GF Leclerc, Dijon 21000, FRANCE.
| |
Collapse
|
2
|
Mary R, Chalmin F, Accogli T, Bruchard M, Hibos C, Melin J, Truntzer C, Limagne E, Derangère V, Thibaudin M, Humblin E, Boidot R, Chevrier S, Arnould L, Richard C, Klopfenstein Q, Bernard A, Urade Y, Harker JA, Apetoh L, Ghiringhelli F, Végran F. Hematopoietic Prostaglandin D2 Synthase Controls Tfh/Th2 Communication and Limits Tfh Antitumor Effects. Cancer Immunol Res 2022; 10:900-916. [PMID: 35612500 DOI: 10.1158/2326-6066.cir-21-0568] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2021] [Revised: 12/06/2021] [Accepted: 04/27/2022] [Indexed: 11/16/2022]
Abstract
T follicular helper (Tfh) cells are a subset of CD4+ T cells essential in immunity and have a role in helping B cells produce antibodies against pathogens. However, their role during cancer progression remains unknown. The mechanism of action of Tfh cells remains elusive because contradictory data have been reported on their protumor or antitumor responses in human and murine tumors. Like Tfh cells, Th2 cells are also involved in humoral immunity and are regularly associated with tumor progression and poor prognosis, mainly through their secretion of IL4. Here, we showed that Tfh cells expressed hematopoietic prostaglandin D2 (PGD2) synthase in a pSTAT1/pSTAT3-dependent manner. Tfh cells produced PGD2, which led to recruitment of Th2 cells via the PGD2 receptor chemoattractant receptor homologous molecule expressed on Th type 2 cells (CRTH2) and increased their effector functions. This cross-talk between Tfh and Th2 cells promoted IL4-dependent tumor growth. Correlation between Th2 cells, Tfh cells, and hematopoietic PGD2 synthase was observed in different human cancers and associated with outcome. This study provides evidence that Tfh/Th2 cross-talk through PGD2 limits the antitumor effects of Tfh cells and, therefore, could serve as a therapeutic target.
Collapse
Affiliation(s)
- Romain Mary
- Faculté des Sciences de Santé, Université Bourgogne Franche-Comté, Dijon, France.,CRI INSERM UMR1231 "Lipids, Nutrition and Cancer", Dijon, France.,LipSTIC LabEx, Dijon, France
| | - Fanny Chalmin
- CRI INSERM UMR1231 "Lipids, Nutrition and Cancer", Dijon, France.,LipSTIC LabEx, Dijon, France
| | - Théo Accogli
- Faculté des Sciences de Santé, Université Bourgogne Franche-Comté, Dijon, France.,CRI INSERM UMR1231 "Lipids, Nutrition and Cancer", Dijon, France.,LipSTIC LabEx, Dijon, France
| | - Mélanie Bruchard
- Faculté des Sciences de Santé, Université Bourgogne Franche-Comté, Dijon, France.,CRI INSERM UMR1231 "Lipids, Nutrition and Cancer", Dijon, France.,LipSTIC LabEx, Dijon, France.,Centre Georges François Leclerc, Dijon, France
| | - Christophe Hibos
- Faculté des Sciences de Santé, Université Bourgogne Franche-Comté, Dijon, France.,CRI INSERM UMR1231 "Lipids, Nutrition and Cancer", Dijon, France.,LipSTIC LabEx, Dijon, France
| | - Joséphine Melin
- LipSTIC LabEx, Dijon, France.,Centre Georges François Leclerc, Dijon, France
| | | | | | - Valentin Derangère
- Faculté des Sciences de Santé, Université Bourgogne Franche-Comté, Dijon, France.,Centre Georges François Leclerc, Dijon, France
| | | | - Etienne Humblin
- CRI INSERM UMR1231 "Lipids, Nutrition and Cancer", Dijon, France.,Precision Immunology Institute, New York, New York
| | - Romain Boidot
- Faculté des Sciences de Santé, Université Bourgogne Franche-Comté, Dijon, France.,Centre Georges François Leclerc, Dijon, France
| | | | | | - Corentin Richard
- Faculté des Sciences de Santé, Université Bourgogne Franche-Comté, Dijon, France.,Centre Georges François Leclerc, Dijon, France
| | | | - Antoine Bernard
- Faculté des Sciences de Santé, Université Bourgogne Franche-Comté, Dijon, France.,CRI INSERM UMR1231 "Lipids, Nutrition and Cancer", Dijon, France.,LipSTIC LabEx, Dijon, France
| | - Yoshihiro Urade
- Intemational Institute for Integrative Sleep Medicine, University of Tsukuba, Tsukuba, Japan
| | - James A Harker
- National Heart & Lung Institute, Imperial College London, London, United Kingdom
| | - Lionel Apetoh
- Faculté des Sciences de Santé, Université Bourgogne Franche-Comté, Dijon, France.,CRI INSERM UMR1231 "Lipids, Nutrition and Cancer", Dijon, France.,LipSTIC LabEx, Dijon, France
| | - François Ghiringhelli
- Faculté des Sciences de Santé, Université Bourgogne Franche-Comté, Dijon, France.,CRI INSERM UMR1231 "Lipids, Nutrition and Cancer", Dijon, France.,LipSTIC LabEx, Dijon, France.,Centre Georges François Leclerc, Dijon, France
| | - Frédérique Végran
- Faculté des Sciences de Santé, Université Bourgogne Franche-Comté, Dijon, France.,CRI INSERM UMR1231 "Lipids, Nutrition and Cancer", Dijon, France.,LipSTIC LabEx, Dijon, France.,Centre Georges François Leclerc, Dijon, France
| |
Collapse
|
3
|
Bruchard M, Geindreau M, Perrichet A, Truntzer C, Ballot E, Boidot R, Racoeur C, Barsac E, Chalmin F, Hibos C, Baranek T, Paget C, Ryffel B, Rébé C, Paul C, Végran F, Ghiringhelli F. Recruitment and activation of type 3 innate lymphoid cells promote antitumor immune responses. Nat Immunol 2022; 23:262-274. [DOI: 10.1038/s41590-021-01120-y] [Citation(s) in RCA: 15] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2021] [Accepted: 12/13/2021] [Indexed: 12/28/2022]
|
4
|
Niogret J, Berger H, Rebe C, Mary R, Ballot E, Truntzer C, Thibaudin M, Derangère V, Hibos C, Hampe L, Rageot D, Accogli T, Joubert P, Routy B, Harker J, Vegran F, Ghiringhelli F, Chalmin F. Follicular helper-T cells restore CD8 +-dependent antitumor immunity and anti-PD-L1/PD-1 efficacy. J Immunother Cancer 2021; 9:jitc-2020-002157. [PMID: 34103351 PMCID: PMC8190041 DOI: 10.1136/jitc-2020-002157] [Citation(s) in RCA: 53] [Impact Index Per Article: 17.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/20/2021] [Indexed: 01/22/2023] Open
Abstract
Background T follicular helper cells (Tfh) are essential to shape B cell response during germinal center formation. Tfh accumulation has been reported in various human cancers, with positive or negative prognostic roles. However, the mechanisms explaining the accumulation of Tfh and their role in cancer remain obscure. Methods In vitro differentiated and mouse cell sorted Tfh phenotype was evaluated by flow cytometry and quantitative PCR (qPCR). Antitumor effect of Tfh was evaluated by adoptive transfer in different tumor-bearing mice models. The involvement of immune cells, cytokines and chemokines was evaluated, using depleting antibodies. Chemokines and cytokines expression and production were evaluated by qPCR and ELISA. In human, the impact of immune cells and chemokines on survival was evaluated by analyzing transcriptomic data from public databases and from our own patient cohorts. Results In this study, we show that Tfh exert an antitumor immune effect in a CD8+-dependent manner. Tfh produce interleukin-21, which sustains proliferation, viability, cytokine production and cytotoxic functions of exhausted T cells. The presence of Tfh is required for efficacy of antiprogrammed cell death ligand-1 therapy. Tfh accumulate in the tumor bed and draining lymph nodes in different mouse cancer models. This recruitment is due to the capacity of transforming growth factor β to drive Chemokine (C-X-C motif) Ligand 13 expression, a chemoattractant of Tfh, by intratumor CD8+ T cells. Accumulation of Tfh and exhausted CD8+ T cells predicts cancer outcome in various cancer types. In patients treated with anti-programmed cell death-1 mAb, accumulation of Tfh and CD8+ at the tumor site is associated with outcome. Conclusion This study provides evidence that CD8+/Tfh crosstalk is important in shaping antitumor immune response generated by immunotherapy.
Collapse
Affiliation(s)
- Julie Niogret
- Centre de Recherche INSERM LNC-UMR1231, Dijon, France.,Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France.,Univ Burgundy Franche Comte, Dijon, France
| | - Hélène Berger
- Centre de Recherche INSERM LNC-UMR1231, Dijon, France.,Univ Burgundy Franche Comte, Dijon, France
| | - Cédric Rebe
- Centre de Recherche INSERM LNC-UMR1231, Dijon, France.,Univ Burgundy Franche Comte, Dijon, France.,Cancer Biology Transfer Platform, Centre Georges-François Leclerc, Dijon, France.,Genetic and Immunology Medical Institute, Dijon, France
| | - Romain Mary
- Centre de Recherche INSERM LNC-UMR1231, Dijon, France.,Univ Burgundy Franche Comte, Dijon, France
| | - Elise Ballot
- Cancer Biology Transfer Platform, Centre Georges-François Leclerc, Dijon, France.,Genetic and Immunology Medical Institute, Dijon, France
| | - Caroline Truntzer
- Univ Burgundy Franche Comte, Dijon, France.,Cancer Biology Transfer Platform, Centre Georges-François Leclerc, Dijon, France.,Genetic and Immunology Medical Institute, Dijon, France
| | - Marion Thibaudin
- Centre de Recherche INSERM LNC-UMR1231, Dijon, France.,Univ Burgundy Franche Comte, Dijon, France.,Cancer Biology Transfer Platform, Centre Georges-François Leclerc, Dijon, France.,Genetic and Immunology Medical Institute, Dijon, France
| | - Valentin Derangère
- Centre de Recherche INSERM LNC-UMR1231, Dijon, France.,Univ Burgundy Franche Comte, Dijon, France.,Cancer Biology Transfer Platform, Centre Georges-François Leclerc, Dijon, France.,Genetic and Immunology Medical Institute, Dijon, France
| | - Christophe Hibos
- Centre de Recherche INSERM LNC-UMR1231, Dijon, France.,Univ Burgundy Franche Comte, Dijon, France
| | - Léa Hampe
- Centre de Recherche INSERM LNC-UMR1231, Dijon, France.,Cancer Biology Transfer Platform, Centre Georges-François Leclerc, Dijon, France
| | | | - Théo Accogli
- Institut Universitaire de Cardiologie et de Pneumologie de Québec, Laval University, Quebec City, Quebec, Canada
| | - Philippe Joubert
- Institut Universitaire de Cardiologie et de Pneumologie de Québec, Laval University, Quebec City, Quebec, Canada
| | - Bertrand Routy
- Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, QC, Canada
| | - James Harker
- National Heart and Lung Institute, Imperial College London, London, UK
| | - Frederique Vegran
- Centre de Recherche INSERM LNC-UMR1231, Dijon, France.,Univ Burgundy Franche Comte, Dijon, France
| | - Francois Ghiringhelli
- Centre de Recherche INSERM LNC-UMR1231, Dijon, France .,Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France.,Univ Burgundy Franche Comte, Dijon, France.,Cancer Biology Transfer Platform, Centre Georges-François Leclerc, Dijon, France.,Genetic and Immunology Medical Institute, Dijon, France
| | - Fanny Chalmin
- Centre de Recherche INSERM LNC-UMR1231, Dijon, France.,Cancer Biology Transfer Platform, Centre Georges-François Leclerc, Dijon, France
| |
Collapse
|
5
|
Bernard A, Hibos C, Richard C, Viltard E, Chevrier S, Lemoine S, Melin J, Humblin E, Mary R, Accogli T, Chalmin F, Bruchard M, Peixoto P, Hervouet E, Apetoh L, Ghiringhelli F, Végran F, Boidot R. The Tumor Microenvironment Impairs Th1 IFNγ Secretion through Alternative Splicing Modifications of Irf1 Pre-mRNA. Cancer Immunol Res 2021; 9:324-336. [PMID: 33419764 DOI: 10.1158/2326-6066.cir-19-0679] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2019] [Revised: 06/26/2020] [Accepted: 01/06/2021] [Indexed: 11/16/2022]
Abstract
It is clearly established that the immune system can affect cancer response to therapy. However, the influence of the tumor microenvironment (TME) on immune cells is not completely understood. In this respect, alternative splicing is increasingly described to affect the immune system. Here, we showed that the TME, via a TGFβ-dependent mechanism, increased alternative splicing events and induced the expression of an alternative isoform of the IRF1 transcription factor (IRF1Δ7) in Th1 cells. We found that the SFPQ splicing factor (splicing factor, proline- and glutamine-rich) was responsible for the IRF1Δ7 production. We also showed, in both mice and humans, that the IRF1 alternative isoform altered the full-length IRF1 transcriptional activity on the Il12rb1 promoter, resulting in decreased IFNγ secretion in Th1 cells. Thus, the IRF1Δ7 isoform was increased in the TME, and inhibiting IRF1Δ7 expression could potentiate Th1 antitumor responses.
Collapse
Affiliation(s)
- Antoine Bernard
- CRI INSERM UMR1231 "Lipids, Nutrition and Cancer," Team "CAdIR," Dijon, Burgundy, France.,Faculté des Sciences de Santé, Université Bourgogne Franche-Comté, Dijon, Burgundy, France.,Centre Georges François Leclerc, Dijon, Burgundy, France
| | - Christophe Hibos
- CRI INSERM UMR1231 "Lipids, Nutrition and Cancer," Team "CAdIR," Dijon, Burgundy, France.,Faculté des Sciences de Santé, Université Bourgogne Franche-Comté, Dijon, Burgundy, France
| | - Corentin Richard
- Faculté des Sciences de Santé, Université Bourgogne Franche-Comté, Dijon, Burgundy, France.,Centre Georges François Leclerc, Dijon, Burgundy, France
| | - Etienne Viltard
- CRI INSERM UMR1231 "Lipids, Nutrition and Cancer," Team "CAdIR," Dijon, Burgundy, France.,Faculté des Sciences de Santé, Université Bourgogne Franche-Comté, Dijon, Burgundy, France
| | - Sandy Chevrier
- Centre Georges François Leclerc, Dijon, Burgundy, France
| | - Sophie Lemoine
- Genomic Platform, Institut de Biologie de l'ENS, Paris, France
| | - Joséphine Melin
- Faculté des Sciences de Santé, Université Bourgogne Franche-Comté, Dijon, Burgundy, France.,LipSTIC LabEx, Dijon, Burgundy, France
| | - Etienne Humblin
- CRI INSERM UMR1231 "Lipids, Nutrition and Cancer," Team "CAdIR," Dijon, Burgundy, France.,Faculté des Sciences de Santé, Université Bourgogne Franche-Comté, Dijon, Burgundy, France
| | - Romain Mary
- CRI INSERM UMR1231 "Lipids, Nutrition and Cancer," Team "CAdIR," Dijon, Burgundy, France.,Faculté des Sciences de Santé, Université Bourgogne Franche-Comté, Dijon, Burgundy, France
| | - Théo Accogli
- CRI INSERM UMR1231 "Lipids, Nutrition and Cancer," Team "CAdIR," Dijon, Burgundy, France.,Faculté des Sciences de Santé, Université Bourgogne Franche-Comté, Dijon, Burgundy, France
| | - Fanny Chalmin
- CRI INSERM UMR1231 "Lipids, Nutrition and Cancer," Team "CAdIR," Dijon, Burgundy, France
| | - Mélanie Bruchard
- CRI INSERM UMR1231 "Lipids, Nutrition and Cancer," Team "CAdIR," Dijon, Burgundy, France.,Faculté des Sciences de Santé, Université Bourgogne Franche-Comté, Dijon, Burgundy, France.,Centre Georges François Leclerc, Dijon, Burgundy, France
| | - Paul Peixoto
- INSERM UMR1098 "Interactions Hôte-Greffon-Tumeur & Ingénierie Cellulaire et Génique," Besançon, France
| | - Eric Hervouet
- INSERM UMR1098 "Interactions Hôte-Greffon-Tumeur & Ingénierie Cellulaire et Génique," Besançon, France
| | - Lionel Apetoh
- CRI INSERM UMR1231 "Lipids, Nutrition and Cancer," Team "CAdIR," Dijon, Burgundy, France.,Faculté des Sciences de Santé, Université Bourgogne Franche-Comté, Dijon, Burgundy, France
| | - François Ghiringhelli
- CRI INSERM UMR1231 "Lipids, Nutrition and Cancer," Team "CAdIR," Dijon, Burgundy, France.,Faculté des Sciences de Santé, Université Bourgogne Franche-Comté, Dijon, Burgundy, France.,Centre Georges François Leclerc, Dijon, Burgundy, France
| | - Frédérique Végran
- CRI INSERM UMR1231 "Lipids, Nutrition and Cancer," Team "CAdIR," Dijon, Burgundy, France. .,Faculté des Sciences de Santé, Université Bourgogne Franche-Comté, Dijon, Burgundy, France.,Centre Georges François Leclerc, Dijon, Burgundy, France
| | - Romain Boidot
- CRI INSERM UMR1231 "Lipids, Nutrition and Cancer," Team "CAdIR," Dijon, Burgundy, France. .,Faculté des Sciences de Santé, Université Bourgogne Franche-Comté, Dijon, Burgundy, France.,Centre Georges François Leclerc, Dijon, Burgundy, France.,UMR CNRS 6302, Dijon, Burgundy, France
| |
Collapse
|